Remembering Wilko Johnson: A Pancreatic Cancer Story Unlike Most

What the BBC reported

Wilko Johnson played the chopping, machine-gun guitar in Dr Feelgood. He later acted in Game of Thrones. He died at home on the evening of Monday 21 November 2022, at 75. The statement from his family and band did not give a cause, and this page will not guess at one.

The part he made public, in detail, was what happened ten years earlier.

The BBC reported that Johnson was first told he had a terminal case of pancreatic cancer. He turned down chemotherapy. "The decision was quite easy - chemotherapy could do no more than extend my life for a relatively short period and I thought I'd just rather enjoy the health that was left to me," he told BBC Radio 5 Live. He played a farewell tour instead.

Then, the BBC reported, later tests found something different. The tumor was in fact a rare and less aggressive neuroendocrine tumor. He had an 11-hour operation that removed his pancreas, his spleen, and parts of his stomach and intestines. He was declared cancer-free in 2014. He kept playing live; his last show was at Shepherd's Bush Empire on 18 October 2022.

Two diseases, one name

This is the heart of the story, and it is a fact about pathology rather than about luck.

"Pancreatic cancer" in ordinary speech means one thing: adenocarcinoma of the pancreatic ducts. NCI's clinical summary reports that duct cell carcinoma makes up about 90% of pancreatic cancers. It grows fast, it spreads early, and it is the disease behind the grim reputation.

Pancreatic neuroendocrine tumors are different from the first cell onward. They start in the hormone-producing islet cells rather than the enzyme-producing duct cells. NCI keeps an entirely separate treatment summary for them, which is the clearest signal there is that they are not a variant of the same illness.

They usually grow more slowly. Some make hormones and cause odd, systemic symptoms — low blood sugar, flushing, stubborn stomach ulcers, watery diarrhea. Many make nothing and are found because of their size or position. And surgery is far more often on the table, because a slower tumor is more likely to still be removable when it is found.

Why the first answer was wrong, and why that is normal

Both tumors sit in the same organ. Both show up as a mass on a CT scan. Neither can be told apart by imaging alone with any confidence.

The difference is made under a microscope, and then by staining the tissue for markers such as chromogranin A and synaptophysin, and by counting how many cells are actively dividing. That last number — the Ki-67 index — separates a slow tumor from an aggressive one and steers the whole treatment plan.

A first working diagnosis is a reasonable guess based on what a scan shows. A final diagnosis needs tissue. When the two disagree, the tissue wins. Our page on how a cancer diagnosis is made explains the sequence, and why "we are waiting on pathology" is a real answer rather than a delay.

When to get checked

The symptoms below do not point to one tumor type. They point to the pancreas, and that is enough reason to be seen:

• Yellow skin or eyes, dark urine, or pale, greasy stools that float.
• Weight falling off without a diet behind it.
• A steady ache high in the abdomen that goes through to the back.
• Diabetes that starts abruptly in an adult, or long-steady diabetes that suddenly will not settle.
• Repeated low blood sugar, flushing, or watery diarrhea with no infection — the pattern that can point to a hormone-producing tumor.

There is no screening test for pancreatic cancer in people at average risk. People with a strong family history or an inherited syndrome may be offered surveillance by a specialist.

What the numbers say, and about whom

The American Cancer Society projects about 67,530 new pancreatic cancer diagnoses in the United States in 2026 and about 52,740 deaths; SEER, the federal cancer surveillance program, carries those projections alongside its own measurements. Five-year relative survival across all stages, as measured by SEER for 2016 to 2022, is 13.7%, and 51% of cases are already at a distant stage when found.

Those figures are dominated by duct cell adenocarcinoma, because that is nine cases in ten. They are not the figures for neuroendocrine tumors, which SEER counts separately and which behave very differently. A statistic quoted for "pancreatic cancer" is almost always a statistic about the common type.

They also describe a large group of people diagnosed years ago. No one in that table is you.

What this does not mean

Johnson's outcome was not the result of declining chemotherapy, and reading it that way would be a serious error. It came from a corrected diagnosis and then a very large operation. He was treated, and treated hard.

Nor does his story mean that a second opinion overturns most diagnoses. It usually confirms them. What it does mean is that asking exactly which cell type a tumor came from is a fair and useful question, and one every pathology report answers.

And "cancer-free" after surgery is a description of a moment, not a guarantee. Neuroendocrine tumors can return years later, which is why follow-up scans continue long after treatment ends. Our guide to life after treatment covers what that surveillance involves.

Sources

• BBC News: Wilko Johnson — Dr Feelgood guitarist dies, aged 75
• NCI PDQ: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (Health Professional Version)
• NCI PDQ: Pancreatic Cancer Treatment (Health Professional Version)
• NCI SEER Cancer Stat Facts: Pancreatic Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.